Guanylhydrazones for Treatment of Postoperative Intestinal Inflammation

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of guanylhydrazones or their salts, such as Semapimod (CNI-1493) or CPSI-2364, as a preventative or therapeutic treatment for postoperative intestinal inflammation, postoperative ileus, and ischemia-reperfusion injury. The method involves administering these compounds, typically before surgery, to reduce or prevent the inflammatory responses commonly triggered by surgical procedures involving the intestines. The compounds act by inhibiting specific inflammatory signaling pathways in intestinal tissue, particularly the p38-MAPK pathway in resident macrophages, thereby reducing inflammation, muscle dysfunction, and complications without impairing wound healing.

Use CasesContent extracted from patent full text and abstract with AI.

• Prophylactic treatment in patients undergoing abdominal or gastrointestinal surgery to prevent post-surgical intestinal inflammation and ileus.
• Pre-treatment of transplant recipients (e.g., small bowel transplantation) to prevent ischemia-reperfusion injury and graft dysfunction.
• Adjunct therapy in cardiothoracic, orthopedic, or trauma surgery where manipulation of the gut may occur.
• Preoperative intervention to reduce risk of bacterial translocation and infectious complications.
• Use in animal models or veterinary applications to improve postsurgical recovery in animals subjected to invasive surgeries involving the intestines.

BenefitsContent extracted from patent full text and abstract with AI.

• Prevents or significantly reduces the incidence and severity of postoperative intestinal inflammation and ileus, leading to faster recovery and shorter hospital stays.
• Reduces ischemia-reperfusion injury after transplantation, preserving graft function and decreasing complications.
• Targets specific molecular pathways (such as p38-MAPK), providing a mechanism-based approach to inflammation control.
• Can be administered in a variety of ways (oral, intravenous, etc.), offering dosing flexibility to meet different clinical needs.
• Does not impair critical healing processes like intestinal anastomotic wound healing, ensuring safe use around surgical procedures.
• Decreases risk of secondary complications such as bacterial translocation, sepsis, and extended ileus, which are associated with high morbidity and mortality.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A method is provided, comprising administering at least one guanylhydrazone or salt thereof or a combination thereof to a subject to prevent or ameliorate in said subject at least one of postoperative intestinal inflammation, postoperative ileus, ischemia reperfusion injury, or a combination thereof.